What are the indications, dosing regimens, treatment durations, contraindications, and common adverse effects of Augmentin (amoxicillin + clavulanate potassium)?

Augmentin (Amoxicillin-Clavulanate): Clinical Overview

Augmentin is a first-line antibiotic combining amoxicillin with clavulanate (a β-lactamase inhibitor) that provides broad-spectrum coverage against common respiratory and soft tissue pathogens, including β-lactamase-producing organisms. 1

Indications

Augmentin is indicated for bacterial infections where β-lactamase-producing organisms are suspected or confirmed:

Respiratory Tract Infections

• Acute bacterial rhinosinusitis - particularly when symptoms are persistent (>10 days), worsening, or severe 2, 3
• Acute otitis media - especially in children who have received amoxicillin in the previous 30 days, those with concurrent conjunctivitis, or when coverage for Moraxella catarrhalis is desired 4, 2
• Community-acquired pneumonia - as first-line therapy for hospitalized patients, often combined with a macrolide 5
• Acute exacerbations of chronic bronchitis 6, 7

Other Infections

• Skin and soft tissue infections - including impetigo, cellulitis, and wound infections caused by Staphylococcus aureus (MSSA) and Streptococcus pyogenes 8
• Urinary tract infections - both uncomplicated and complicated 9
• Intra-abdominal and pelvic infections involving mixed aerobic/anaerobic organisms 9

Dosing Regimens

Adults

Standard-dose regimen:

• 500-875 mg every 12 hours (based on amoxicillin component) 6, 10
• The 875/125 mg twice-daily formulation is as effective as 500/125 mg three times daily with better tolerability 10

High-dose regimen (for resistant pathogens):

• 4 g/day of amoxicillin with 250 mg/day of clavulanate in two divided doses 1
• The pharmacokinetically enhanced formulation (Augmentin XR) at 2,000/125 mg twice daily extends therapeutic levels to eradicate organisms with amoxicillin MICs ≤4 mcg/mL 7
• High-dose therapy is indicated when penicillin-nonsusceptible S. pneumoniae is suspected 1

Pediatric Patients

Standard-dose regimen:

• 22.5-45 mg/kg/day (based on amoxicillin component) in 2 divided doses 6, 8

High-dose regimen:

• 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in 2 divided doses 1, 4
• The pediatric formulation provides a 14:1 ratio of amoxicillin to clavulanate, which reduces diarrhea compared to other ratios 1, 4
• Maximum pediatric dose should not exceed adult dosing 1

Treatment Duration

5-10 days is the recommended duration for most bacterial infections 3:

• Acute bacterial rhinosinusitis: 5-10 days 3
• Acute otitis media: 7-10 days (shorter courses of 5-7 days may be appropriate for older children with uncomplicated disease) 4, 2
• Acute exacerbations of chronic bronchitis: 5-7 days (a 5-day course of high-dose formulation is as effective as 7 days of standard dosing) 7
• Community-acquired pneumonia: 7-10 days 5

Contraindications

Absolute contraindications 11:

• History of allergic reactions to any penicillin
• Previous history of cholestatic jaundice or hepatic dysfunction associated with Augmentin

Important caveat: Cross-reactivity between penicillins and cephalosporins is lower than historically reported (previously cited at ~10%, but likely an overestimate). Cephalosporins with distinct chemical structures (cefdinir, cefuroxime, cefpodoxime, ceftriaxone) are highly unlikely to cross-react and can be used in penicillin-allergic patients except those with immediate hypersensitivity reactions 4

Common Adverse Effects

Gastrointestinal Effects (Most Common)

• Diarrhea: 3-12% of patients, more common with three-times-daily dosing than twice-daily 1, 11
• When clavulanate dose exceeds approximately 10 mg/kg/day, diarrhea becomes more problematic 1
• Nausea and vomiting: 2-7% 11
• Taking with food may reduce gastrointestinal side effects 2, 11

Dermatologic Effects

• Rash: 1-5% 11
• Contact dermatitis (diaper rash): 3.5-6% in pediatric patients 11
• Serious reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) are rare but reported 11

Hepatic Effects

• Moderate rise in AST/ALT may occur 11
• Hepatic dysfunction (cholestatic, hepatocellular, or mixed) is infrequent but can be severe and usually reversible 11
• More common in elderly, males, or patients on prolonged treatment 11

Other Adverse Effects

• Hypersensitivity reactions: urticaria, angioedema, serum sickness-like reactions, anaphylaxis (rare) 11
• Hematologic: reversible thrombocytopenia, leukopenia, eosinophilia 11
• CNS effects: agitation, anxiety, confusion, dizziness (rare) 11
• Tooth discoloration: brown, yellow, or gray staining (rare, mostly pediatric, reduced with brushing) 11

Key Clinical Considerations

Antimicrobial Spectrum

• Excellent activity against Streptococcus pneumoniae (including penicillin-intermediate strains with high-dose formulations) 1
• Effective coverage for β-lactamase-producing Haemophilus influenzae (58-82% susceptible to standard amoxicillin, nearly 100% with clavulanate) 4, 1
• Complete coverage for β-lactamase-producing Moraxella catarrhalis (90-100% produce β-lactamase) 6
• Amoxicillin is the most active oral β-lactam against streptococci due to excellent bioavailability 1

Resistance Considerations

• High-dose formulations overcome relative penicillin resistance in S. pneumoniae by achieving higher serum and tissue concentrations 1
• Clavulanate addition does not drive resistance development 1
• Amoxicillin-clavulanate is included in the WHO AWaRe "Access" group, prioritizing narrow-spectrum agents with low resistance potential 12

Practical Prescribing Pitfalls

• Do not prescribe for viral upper respiratory infections - no benefit, only exposes patients to adverse effects and promotes resistance 2
• Avoid azithromycin and oral third-generation cephalosporins as first-line for respiratory infections due to S. pneumoniae resistance 2
• Use high-dose formulations when recent antibiotic exposure (within 30 days), daycare attendance, age <2 years, or geographic areas with high resistance rates 4, 2
• Twice-daily dosing reduces diarrhea compared to three-times-daily regimens 1, 10